Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Works by Horblyuk, Ruslan
Results: 12
1
2
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0191722
- By:
- Publication type:
- Article
3
Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography.
- Published in:
- Breast Cancer Research & Treatment, 2013, v. 138, n. 3, p. 879, doi. 10.1007/s10549-013-2466-5
- By:
- Publication type:
- Article
4
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
- Published in:
- 2018
- By:
- Publication type:
- journal article
5
Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
- Published in:
- 2016
- By:
- Publication type:
- journal article
6
Economic and clinical evaluation of fondaparinux vs. enoxaparin for thromboprophylaxis following general surgery.
- Published in:
- Current Medical Research & Opinion, 2009, v. 25, n. 5, p. 1081, doi. 10.1185/03007990902837117
- By:
- Publication type:
- Article
7
Consequences of major bleeding in hospitalized patients with non-ST segment elevation acute coronary syndromes receiving injectable anticoagulants.
- Published in:
- Current Medical Research & Opinion, 2009, v. 25, n. 2, p. 413, doi. 10.1185/03007990802649133
- By:
- Publication type:
- Article
8
Economic Analysis of Add--on Therapy with Thiazolidinedione (TZD) versus Insulin (INS) to Metformin (MET) Monotherapy.
- Published in:
- Diabetes, 2007, v. 56, p. A653
- By:
- Publication type:
- Article
9
Budgetary Impact of Thiazolidinedione (TZD) Add-On Therapy Relative to Insulin (INS) Add-On Therapy in Individuals Treated with Sulfonylureas (SU): A Third Party Payer's Perspective.
- Published in:
- Diabetes, 2007, v. 56, p. A653
- By:
- Publication type:
- Article
10
Triple Therapy with Rosiglitazone (RSG) or Insulin (INS) and Associated Medical Resource Use (MRU) and Costs in Type 2 Diabetes (T2D).
- Published in:
- Diabetes, 2007, v. 56, p. A650
- By:
- Publication type:
- Article
11
Add-On Therapy with Rosiglitazone (RSG)/Metformin (MET) as a Fixed-Dose Combination (FDC) vs RSG plus MET or RSG plus Sulfonylurea (SU) as Separate Pills (SP): Retrospective Study of Outcomes and Costs.
- Published in:
- Diabetes, 2007, v. 56, p. A558
- By:
- Publication type:
- Article
12
Impact of Multiple Medication Use for Treatment of Diabetes and Lipid Disorders on Therapy Compliance, LDL, and HbA1c.
- Published in:
- Diabetes, 2007, v. 56, p. A553
- By:
- Publication type:
- Article